Silver Book reference

Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults

6 Matching Facts

Search matching Facts:
No results to display
    • Use of shingles vaccine could save $82 to $103 million
      Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
    • Potential savings from shingles vaccine
      Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
    • Potential cost effectiveness of shingles vaccines
      The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…  
    • Shingles vaccine would reduce healthcare use
      Use of the shingles vaccine in immunocompetent adults could eliminate more than 300,000 outpatient visits, 375,000 prescriptions, 9,700 emergency room visits, and 10,000 hospitalizations.  
    • Shingles causes an average of 129 hours lost work per episode
      Patients with shingles (including those progressing to postherpetic neuralgia) lose an average of over 129 hours of work per episode, including losses of 12 or more hours of work time  
    • Lost work due to shingles
      Shingles patients lose an average 129 hours of work per episode.